Cargando…

Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study

BACKGROUND: This phase 1 first-in-human study aimed to determine the maximum-tolerated dose (MTD), dose-limiting toxicities, and safety of E6201, and to establish recommended dosing in patients with advanced solid tumours, expanded to advanced melanoma. METHODS: Part A (dose escalation): sequential...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tibes, Raoul, Borad, Mitesh J., Dutcus, Corina E., Reyderman, Larisa, Feit, Kevie, Eisen, Andrew, Verbel, David A., Von Hoff, Daniel D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008465/ https://www.ncbi.nlm.nih.gov/pubmed/29867224 http://dx.doi.org/10.1038/s41416-018-0099-5

Ejemplares similares

Demographic risk factors for lymphoma in Australian dogs: 6201 cases
por: Bennett, Peter F., et al.
Publicado: (2018)

Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status
por: Byron, Sara A, et al.
Publicado: (2012)

Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma
por: Babiker, Hani M, et al.
Publicado: (2017)

Safety evaluation of the food enzyme pectinesterase from the genetically modified Trichoderma reesei strain RF6201
por: Lambré, Claude, et al.
Publicado: (2023)

The Impact of Concomitant Medication Use on Patient Eligibility for Phase I Cancer Clinical Trials
por: Borad, Mitesh J., et al.
Publicado: (2012)

Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma [Corrigendum]
por: Babiker, HM, et al.
Publicado: (2019)

Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant
por: Dayal, Satish, et al.
Publicado: (2021)

Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours
por: Evans, T. R. Jeffry, et al.
Publicado: (2019)

Effect of gastric acid‐reducing agents on the pharmacokinetics and efficacy of lemborexant
por: Landry, Ishani, et al.
Publicado: (2020)

Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant
por: Landry, Ishani, et al.
Publicado: (2021)

Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function
por: Tan, Antoinette R., et al.
Publicado: (2015)

Intravenous Perampanel as an Interchangeable Alternative to Oral Perampanel: A Randomized, Crossover, Phase I Pharmacokinetic and Safety Study
por: Hussein, Ziad, et al.
Publicado: (2022)

Effects of Lemborexant on the Pharmacokinetics of Oral Contraceptives: Results From a Phase 1 Drug‐Drug Interaction Study in Healthy Females
por: Landry, Ishani, et al.
Publicado: (2021)

Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study
por: Landry, Ishani, et al.
Publicado: (2022)

An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Patients with Advanced Solid Tumors
por: Shumaker, Robert, et al.
Publicado: (2020)

Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies
por: Tibes, Raoul, et al.
Publicado: (2014)

Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia
por: Tibes, Raoul, et al.
Publicado: (2019)

Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease
por: Hayato, Seiichi, et al.
Publicado: (2022)

Marantic Endocarditis Associated with Pancreatic Cancer: A Case Series
por: Jameson, Gayle S., et al.
Publicado: (2009)

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours
por: Infante, Jeffrey R, et al.
Publicado: (2018)

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours
por: Infante, Jeffrey R, et al.
Publicado: (2018)

P579: SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF AZD5991 IN RELAPSED/ REFRACTORY HEMATOLOGIC MALIGNANCIES: A PHASE 1 FIRST-IN-HUMAN STUDY
por: Desai, Pinkal, et al.
Publicado: (2023)

Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome
por: Weiss, Glen J., et al.
Publicado: (2011)

A combined physiologically‐based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease
por: Geerts, Hugo, et al.
Publicado: (2023)

Tumour to Tumour Metastasis of Malignant Melanoma to Intracranial Tumour
por: Shariff, Zakir, et al.
Publicado: (2009)

Advances in systemic therapy for advanced pancreatobiliary malignancies
por: Halfdanarson, Thorvardur R, et al.
Publicado: (2013)

Oncolytic Adenoviruses in Gastrointestinal Cancers
por: Yokoda, Raquel T., et al.
Publicado: (2018)

Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma
por: Conroy, Michael, et al.
Publicado: (2017)

Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To Date
por: Uson Junior, Pedro Luiz Serrano, et al.
Publicado: (2023)

Oral‐facial‐digital syndrome type 1 in males: Congenital heart defects are included in its phenotypic spectrum
por: Bouman, Arjan, et al.
Publicado: (2017)

Skeletal Metastases in Pancreatic Cancer: A Retrospective Study and Review of the Literature
por: Borad, Mitesh J., et al.
Publicado: (2009)

18-FDG PET/CT assessment of basal cell carcinoma with vismodegib
por: Thacker, Curtis A, et al.
Publicado: (2012)

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors
por: Javle, Milind, et al.
Publicado: (2023)

Prolonged duration of response in lenvatinib responders with thyroid cancer
por: Gianoukakis, Andrew G, et al.
Publicado: (2018)

(18)F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer
por: Korn, Ronald L., et al.
Publicado: (2017)

Radiological Diagnosis of Brain Tumours (including Ventriculography)
por: Hardman, T. Garratt
Publicado: (1936)

Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial
por: Kiyota, Naomi, et al.
Publicado: (2017)

Dataset for Phase I randomized clinical trial for safety and tolerability of GET 73 in single and repeated ascending doses including preliminary pharmacokinetic parameters
por: Haass-Koffler, Carolina L., et al.
Publicado: (2017)

Exposure–response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer
por: Hayato, Seiichi, et al.
Publicado: (2018)

FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice
por: Kommalapati, Anuhya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6tamkasucakm743fst3jq938pu